Items where Subject is "cancer drugs - see diseases-cancer-drugs and therapies"

B

Bordeleau, M. E., Robert, F., Gerard, B., Lindqvist, L., Chen, S. M., Wendel, H. G., Brem, B., Greger, H., Lowe, S. W., Porco, J. A., Pelletier, J. (July 2008) Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest, 118 (7). 2651- 2660.

Burgess, D. J., Doles, J., Zender, L., Xue, W., Ma, B., McCombie, W. R., Hannon, G. J., Lowe, S. W., Hemann, M. T. (July 2008) Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A, 105 (25). pp. 9053-9058.

C

Clark, J. W., Camidge, D. R., Kwak, E. L., Maki, R. G., Shapiro, G. I., Chen, I., Tan, W., Randolph, S., Christensen, J. G., Ozeck, M., Tang, Y., Wilner, K. D., Salgia, R. (January 2020) Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. Future Oncol, 16 (1). pp. 4289-4301. ISSN 1479-6694

E

Eifert, C., Powers, R. S. (June 2012) From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets. Nat Rev Cancer, 12 (8). pp. 572-578. ISSN 1474-1768 (Electronic)1474-175X (Linking)

G

Guix, M., de Matos Granja, N., Meszoely, I., Adkins, T. B., Wieman, B. M., Frierson, K. E., Sanchez, V., Sanders, M. E., Grau, A. M., Mayer, I. A., Pestano, G., Shyr, Y., Muthuswamy, S., Calvo, B., Krontiras, H., Krop, I. E., Kelley, M. C., Arteaga, C. L. (February 2008) Short Preoperative Treatment With Erlotinib Inhibits Tumor Cell Proliferation in Hormone Receptor Positive Breast Cancers. J Clin Oncol, 26 (6). pp. 897-906.

H

Hein, N., Bywater, M. J., Stanley, K., Verbrugge, I., Cullinane, C., Baker, A., Zuber, H., Rappaport, A., Drygin, D., Huser, N., Bliesath, J., Ryckman, D. M., Rice, W. G., Lowe, S. W., Johnstone, R. W., Pearson, R. B., McArthur, G. A., Hannan, R. D. (November 2011) Inhibition of RNA Polymerase I Transcription by CX-5461 As a Therapeutic Strategy for the Cancer-Specific Activation of p53 in MLL-Rearranged Acute Myeloid Leukemias. Blood, 118 (21). p. 1548. ISSN 0006-4971

Herrmann, H., Blatt, K., Shi, J. W., Rappaport, A. R., Gleixner, K. V., Cerny-Reiterer, S., Peter, B., Wang, E., Sperr, W. R., Bradner, J. E., Lowe, S. W., Vakoc, C. R., Zuber, J., Valent, P. (November 2011) Small-Molecule Inhibition of BRD4 Is a Novel Promising Approach to Therapeutically Target Leukemia Stem Cells in AML. Blood, 118 (21). p. 3484. ISSN 0006-4971

K

Kan, J. L. C., Griffin, G., Hannon, G. J. (2004) Mining the genome with RNAi to select cancer drug targets. Drug Discovery Today: Therapeutic Strategies, 1 (4). pp. 397-401. ISSN 17406773 (ISSN)

Kani, K., Sordella, R., Mallick, P. (2012) Investigation of acquired resistance to EGFR-targeted therapies in lung cancer using cDNA microarrays. Methods in Molecular Biology, 795. pp. 233-53. ISSN 1940-6029 (Electronic)1064-3745 (Linking)

L

Lee, M. Y., da Silva, B., Ramirez, D. C., Maki, R. G. (May 2019) Novel HMGA2-YAP1 fusion gene in aggressive angiomyxoma. BMJ Case Rep, 12 (5). ISSN 1757-790x

Liao, S. C., Hsu, W. H., Huang, Z. Y., Chuang, K. L., Lin, K. T., Tseng, C. L., Tsai, T. H., Dao, A. H., Su, C. L., Huang, C. F. (December 2019) Bioactivity Evaluation of a Novel Formulated Curcumin. Nutrients, 11 (12). ISSN 2072-6643 (Public Dataset)

M

Mishra, Sushanta Kumar, Millman, Scott Evan, Zhang, Lingbo (December 2022) Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets. Blood. ISSN 0006-4971

Muthuswamy, S. K. (April 2011) Trastuzumab resistance: all roads lead to SRC. Nature Medicine, 17 (4). pp. 416-8. ISSN 1078-8956

N

Neesse, A., Frese, K. K., Chan, D. S., Bapiro, T. E., Howat, W. J., Richards, F. M., Ellenrieder, V., Jodrell, D. I., Tuveson, D. A. (September 2013) SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut, 63 (6). pp. 974-983. ISSN 00175749 (ISSN)

Neesse, A., Krug, S., Gress, T. M., Tuveson, D. A., Michl, P. (2013) Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Onco Targets Ther, 7. pp. 33-43. ISSN 1178-6930 (Print)1178-6930

R

Robert, F., Carrier, M., Rawe, S., Chen, S., Lowe, S. W., Pelletier, J. (May 2009) Altering chemosensitivity by modulating translation elongation. PLoS ONE, 4 (5). e5428.

S

Sawey, E. T., Chanrion, M., Cai, C., Wu, G., Zhang, J., Zender, L., Zhao, A., Busuttil, R. W., Yee, H., Stein, L. D., French, D. M., Finn, Richard S, Lowe, S. W., Powers, S. (March 2011) Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening. Cancer Cell, 19 (3). pp. 347-358. ISSN 1535-6108

Sindhwani, S., Syed, A.M., Ngai, J., Kingston, B.R., Maiorino, L., Rothschild, J., MacMillan, P., Zhang, Y., Rajesh, N.U., Hoang, T., Wu, J.L.Y., Wilhelm, S., Zilman, A., Gadde, S., Sulaiman, A., Ouyang, B., Lin, Z., Wang, L., Egeblad, M., Chan, W.C.W. (January 2020) The entry of nanoparticles into solid tumours. Nat Mater. ISSN 1476-1122 (Public Dataset)

W

Watson, J. (January 2013) Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biology, 3 (1). pp. 2046-2441.

Watson, J. D. (November 2011) Curing "incurable" Cancer. Cancer Discovery, 1 (6). pp. 477-480. ISSN 2159-8274